Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2626596 | 0.83 | CA14 (0.39) | CA14CA12ALDH1A1SMN1; SMN2CA7 | |
| SCHEMBL31350661 | 0.83 | CA14 (0.39) | CA14CA12ALDH1A1SMN1; SMN2CA7 | |
| SCHEMBL19970237 | 0.80 | CA14 (0.33) | CA14CA12ALDH1A1 | |
| SCHEMBL12932471 | 0.79 | CA1 (0.38) | CA14CA12ALDH1A1SMN1; SMN2CA7 | |
| SCHEMBL2327528 | 0.79 | CA1 (0.38) | CA14CA12ALDH1A1SMN1; SMN2CA7 | |
| SCHEMBL10012900 | 0.76 | CA14 (0.35) | CA14CA12ALDH1A1SMN1; SMN2CA7 | |
| SCHEMBL19395796 | 0.74 | CA14 (0.34) | CA14CA12ALDH1A1SMN1; SMN2CA7 | |
| SCHEMBL10010227 | 0.73 | TSHR (0.41) | CA14CA12ALDH1A1CA7CA9 | |
| SCHEMBL7066030 | 0.73 | ALDH1A1 (0.39) | CA14CA12ALDH1A1CA7CA9 | |
| SCHEMBL16977009 | 0.72 | TAS1R3 (0.32) | CA12ALDH1A1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197378-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO PHARMA AS (DK) | 2025-06-19 | — | — | US | disclosed |
| EP-4486737-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO Pharma A/S (DK) | 2025-01-08 | — | — | EP | disclosed |
| WO-2023166172-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO PHARMA A/S (DK) | 2023-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250197378-A1 | SMALL MOLECULE MODULATORS OF IL-17 | IL17A, IL2, IL23R | CA14 3073/4885CA12 3183/4885ALDH1A1 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.